Differences in genomic signatures and opportunities for targeted and immunotherapy treatment between castrate-resistant TMPRSS2:ERG fusion-positive and -negative refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).

Leszek Kotula,Gennady Bratslavsky,Hugh A.G. Fisher,Timothy Byler,Robert John Corona,Joseph Jacob,Alina Basnet,Jon Chung,Julia Andrea Elvin,Jo-Anne Vergilio,James Suh,Shakti Ramkissoon,Sugganth Daniel,Eric Allan Severson,Alexa B. Schrock,Siraj M. Ali,Vincent A. Miller,Jeffrey S. Ross

Differences in genomic signatures and opportunities for targeted and immunotherapy treatment between castrate-resistant TMPRSS2:ERG fusion-positive and -negative refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).

2018

Leszek Kotula
Gennady Bratslavsky
Hugh A.G. Fisher
Timothy Byler
Robert John Corona
Joseph Jacob
Alina Basnet
Jon Chung
Julia Andrea Elvin
Jo-Anne Vergilio
James Suh
Shakti Ramkissoon
Sugganth Daniel
Eric Allan Severson
Alexa B. Schrock
Siraj M. Ali
Vincent A. Miller
Jeffrey S. Ross

5061Background: We hypothesized that sub-categorization of TMPRSS2 fusion status would impact therapy opportunities in patients with clinically advanced CRPC and CRNEPC. Methods: CGP was performed ...

Keywords:

Immunotherapy
Prostate cancer
Pathology
Cancer research
Medicine
TMPRSS2
castrate resistant
Oncology
in patient
Refractory
Internal medicine
Erg

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations